Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Apr 28, 2021 1:05pm
144 Views
Post# 33083306

RE:RE:Chewing the fat. .5 .7 1. doses thoughts

RE:RE:Chewing the fat. .5 .7 1. doses thoughts

However when we get next data if 2 out of 3 or more from patients 16,17 and 18 are CR , then we should fly IMo, that would be very impressive.

enriquesuave wrote:

On average the 1st 12 patients of PH2 got undertreated by 75% and not 30% .  In PH1, of the 3 patients treated at the high dose, only 5 &6 got an optimized treatment, not patient 4.  We need a good 10-15 or more patients in a row treated with optimized procedure to be able to confirm approximate level of efficacy IMO.  

 

 

floatinketucky wrote: The Study will consist of patients who will undergo two (2) PDT treatments employing 0.70 mg/cm^2 of TLD-1433 at Day 0 and Day 180.
https://www.clinicaltrials.gov/ct2/show/record/NCT03945162?term=TLD-1433&draw=2&rank=1

ok we see who is listed to be included in the study.


In phase 1 study:
3 patients got .35 (half a dose)  100% CR AT 90 DAYS  pr-
November 8, 2017
3 patients got .70 (full dose)        67% CR AT 18 MONTHS

This is what I find interesting at least one dirty dozen phase 2 patients got 30 percent under treated or a 70 percent dose. Almost smack dab in the middle of the half dose and full dose. 

Also the phase one study ended at 18 months so no further data was reported. Like the 24 month data...   

You can expect the bean counters to be salavating over the 30 percent under treated data.


So if a patient didn't get (2) PDT treatments employing 0.70 mg/cm^2 of TLD-1433 at Day 0 and Day 180 then they really didn't qualify for the study. 






 

 

 



<< Previous
Bullboard Posts
Next >>